Cat. No. 2855
Alternative Name: CPNQ
Chemical Name: 5-[4-(4-Chlorobenzoyl)-1-piperaziny
Biological ActivityPromotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease. Prevents mutant huntingtin-mediated proteasome dysfunction and reduces α-synuclein-mediated toxicity.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Bodner et al (2006) Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parksinson's diseases. Proc.Natl.Acad.Sci.USA 103 4246.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses B2 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: B2, supplier, Promotes, inclusion, formation, Huntingtons, Parkinsons, parkinson's, diseases, Huntingdons, Neuronal, Metabolism, Huntington's, Tocris Bioscience, Neuronal Metabolism products
Find multiple products by catalog number
New Products in this Area
PCNA inhibitorPladienolide B
mRNA splicing inhibitor; antitumorLin28 1632
RNA binding protein Lin28 inhibitor; promotes mESC differentiation; also bromodomain inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.